Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price target dropped by equities researchers at Morgan Stanley from $20.00 to $18.50 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 12.87% […]
Bausch + Lomb (NYSE:BLCO – Get Free Report) and Signature Eyewear (OTCMKTS:SEYE – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability. Analyst Recommendations This is a breakdown of […]
Renaissance Capital LLC boosted its position in Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 18.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,644 shares of the company’s stock after purchasing an additional 2,125 shares during the quarter. […]
Renaissance Capital LLC raised its holdings in Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 18.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,644 shares of the company’s stock after purchasing an additional 2,125 shares during the quarter. Renaissance Capital […]
Tectonic Advisors LLC grew its position in Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 6.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,416 shares of the company’s stock after acquiring an additional 2,272 shares during the […]